Bristol-Myers Squibb Co logo

Bristol-Myers Squibb Co

BMY
Healthcare|Drug Manufacturers - General|USA
$58.23
-1.10 (-1.85%)
DCF (FCF)
$68.81
Earnings Power
$30.07

Upcoming Data Readouts (57)

May 2026
Est. completion
P1P2Advanced Cancer
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
NCT04396821n=150
May 2026
Est. completion
P2Pancreatic Cancer
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT02451982n=76
Jun 2026
Est. completion
P2Non Small Cell Lung Cancer
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
NCT04933903n=25
Jun 2026
Est. completion
P2Myelodysplastic Syndromes
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
NCT05732961n=70
Jun 2026
Est. completion
P1P2Advanced Cancer
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
NCT04495296n=320
Jul 2026
Est. completion
P2Interstitial Lung Disease
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375n=38
Jul 2026
Est. completion
P1P2Triple-Negative Breast Cancer
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT02393794n=51
Jul 2026
Est. completion
P2Heart Failure
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779n=208
Jul 2026
Est. completion
P4Cardiomyopathy, Hypertrophic
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743n=63
Jul 2026
Est. completion
P3Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976n=606
Jul 2026
Est. completion
P3Psoriasis
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435n=1,466
Jul 2026
Est. completion
P1P2Metastatic Colon Adenocarcinoma
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT04599140n=51
Aug 2026
Est. completion
Gastric Cancer
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria
NCT07481110n=1,000
Oct 2026
Est. completion
P2Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
NCT03607890n=38
Oct 2026
Est. completion
P1P2Multiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354n=260
Nov 2026
Est. completion
Early P1Multiple Myeloma
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT05560399n=7
Nov 2026
Est. completion
P1Malignant Pleural Mesothelioma
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
NCT04162015n=22
Nov 2026
Est. completion
Obstructive Hypertrophic Cardiomyopathy
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06146660n=600
Dec 2026
Est. completion
AML, Adult
Assessment of Geriatric Evaluations Impact on New AML Guidance
NCT05909501n=100
Dec 2026
Est. completion
P2Squamous Cell Carcinoma of the Skin
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
NCT04204837n=61

Awaiting Results (28)

Trials past primary completion date but still active — data readout may be imminent.

Apr 2026
P1P2
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
NCT03610711
Mar 2026
P3
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836
Mar 2026
P1
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
NCT03085173
Feb 2026
P3
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03383458
Feb 2026
P3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03661320
Jan 2026
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
NCT05334719
Dec 2025
P2
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
NCT04702880
Dec 2025
Early P1
Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
NCT05851365
Dec 2025
P2
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
NCT03650894
Nov 2025
Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
NCT03455452

Recent Press Releases